Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.
D000209:Acute-Phase Proteins / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood; D016207:Cytokines / Q000097:blood; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D007378:Interleukins / Q000008:administration & dosage*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D011379:Prognosis; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome; D000098546:Interleukin-21
D000209:Acute-Phase Proteins; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D016207:Cytokines; D007378:Interleukins; D011994:Recombinant Proteins; D000098546:Interleukin-21